NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP 50 Pharmas » AstraZeneca  1    
found files: 13
AstraZeneca »17/02/2007 [Company watch]
AstraZeneca Wins 2nd Award for Investment in China

Following $134millions investment in a manufacturing plant at Wuxi in 2001, AZ have announced a further $35millions investment in the site. In May 2006 AZ announced its intention to invest $100millions in R & D in China....   more»


AstraZeneca »23/03/2007 [Company watch]
AStraZeneca name site for lab expansion plan

AStrazeneca confirm site for their $100Million R & D expansion in China as the Zhangjiang Hi-Tech park in Shanghai with completion due in mid 2007. Recruitrment of scientists is already underway. The Innovation Center China will open in mid-2007 before the establishment of a permanent site that officials are still looking for....   more»


AstraZeneca »24/04/2007 [Company watch]
AStra Zeneca are advertising for :TRANSLATIONAL SCIENTIST for pre-clinical development in cancer research

AStra Zeneca are seeking an experienced scientist to lead pre clinical cancer trials team in the Shanghai Innovation Centre - full job advert below, to be fully operational by 2009...   more»


AstraZeneca »05/09/2007 [Company watch]
AstraZeneca ups research capabilities in China

Singapore, September 5, 2007: China plays an increasingly important role as an emerging market in AstraZeneca‚Äôs global strategy. In line with this strategy, AstraZeneca entered into a strategic partnership with Peking University 3rd Hospital to open its first Clinical Pharmacology Unit (CPU) in China. The unit aims to enhance local clinical research capabilities and speed up access to new medicines to benefit Chinese patients....   more»


AstraZeneca »24/09/2007 [Company watch]
Astra Zeneca to outsource manufacture

Anglo-Swedish drug firm AstraZeneca has today reiterated that it will outsource drug manufacturing 'where there is a sound business case.' The company issued a statement after the publication today of an interview with David Smith, AstraZeneca's executive vice-president of operations, in The Times. The newspaper reported that the company would cease and fully outsource all drug manufacturing operations within the next ten years. AstraZeneca quickly refuted the report claiming that some of Smith's comments had been misinterpreted. But the firm confirmed that part of its global view was to look more seriously at outsourcing, and that it had particular interest in opportunities in India and China. This is likely to be seen as ominous for UK manufacturing and comes just one week after the world's largest pharmaceutical company, Pfizer, revealed its decision to close its only remaining UK manufacturing plant at Sandwich in Kent, resulting in the loss of 420 jobs over the next two years. Earlier this year, AstraZeneca announced its intention to cut 3300 manufacturing jobs worldwide. But Joan Pitt, an AstraZeneca spokeswoman, told Chemistry World that this was not a signal that the company sought to move away from UK-based manufacturing. Richard Ley, a spokesman for the Association of the British Pharmaceutical Industry, told Chemistry World that there is increasing global competition for manufacturing. He warned that in the long term drug research may follow manufacturing out of the UK. 'A great deal of drug manufacturing is high-tech, so it may make more sense for companies to relocate R&D to the same place in order to have scientists working alongside each other,' Ley said....   more»


AstraZeneca »22/10/2007 [Company watch]
AstraZeneca outsources manufacture to China in a bid to reduce costs

AstraZeneca has begun to outsource production of some of its bestselling medicines to low-cost manufacturers in China, Times Online reported. As part of a restructuring drive designed to cut $900 million (¬£440 million) of the drugs group‚Äôs costs by 2010, the drugs giant is to begin purchasing Lactam, a key chemical ingredient used to make Seroquel, its blockbuster schizophrenia drug, from contract manufacturers in China....   more»


AstraZeneca »29/02/2008 [Company watch]
Year End Results for AStra Zeneca - Increase to China Investment

AstraZeneca to increase China investment According to AstraZeneca's annual report released February 26, the company's global net income for 2007 dropped 7.2% to USD 5.63 billion, while sales in China rose by 25% to USD 500 million. The company will increase its China investment with the construction of the AstraZeneca Industrial Park (translated by GB). The park will include facilities for company management, research and development, and staff training. Brief view of Results: Turnover (up) $29,559 Millions R & D Spend (up) $5162 Millions Net Profit B T (down) $7,983 Millions...   more»


AstraZeneca »19/03/2008 [Company watch]
Astra Zeneca's Expansion

Expanding the presence of AstraZeneca (AZN) in the Asia-Pacific region in general and China specifically is a priority for AstraZeneca, according to John Ramsey, AstraZeneca‚Äôs Vice President for Global Development. Ramsey made the remarks in an interview with EView Week. Ramsey stressed that AstraZeneca is interested in developing drugs that address the needs of China‚Äôs population. Toward that end, AstraZeneca has established its Innovation Center China [ICC], which began operations in 2007 and establishes relationships with China‚Äôs universities and medical centers. Because of the company‚Äôs emphasis on China‚Äôs needs, Ramsey can boast that AstraZeneca‚Äôs $100 million investment in China (spread over two to three years) is the largest of any biopharma that is focused on China‚Äôs diseases. The ICC will concentrate on cancer, seeking to learn more about liver cancer, gastric cancer, lung cancer and pre-menopausal breast cancer. It will study the causes of the disease, define biomarkers and identify new targets for innovative drugs. The growing China market for drugs is one reason that AstraZeneca chose to concentrate in China. But just as important was its pool of scientific talent and unique medical needs. Although AstraZeneca China‚Äôs motto is ‚ÄúIn China, For China,‚ÄĚ the staff at ICC has the ability to work with AstraZeneca scientists from around the world. So far, the ICC has put on its staff 40 researchers, 40% of them with PhDs. The target is to hire 60 scientists. AstraZeneca China currently has a total workforce of 2,500....   more»


AstraZeneca »31/03/2008 [Company watch]
China SFDA gets Tough and AZ affected

China's drug regulatory authority is finally responding to curb its damaged reputation by urging its local authorities to take a more proactive role in stemming what is fast becoming a global heparin contamination, sparked by material sourced in the country. According to Chinese media reports, the State Food and Drug Administration (SFDA) issued a message on its website urging its regional offices to boost their supervision of the production methods of heparin manufacturers in their locality. The watchdog has also urged heparin producers to source their raw heparin from registered suppliers only, and issued a plea to heparin manufacturers to ensure they are producing the material in accordance with the approved standards. In addition, the SFDA warned manufacturers that they must take the initiative to closely follow the clinical effects of their products that are on the market and if any problems are linked back to their manufacturing facilities, they must halt production immediately and recall any implicated products from the market....   more»


AstraZeneca »26/01/2009 [Company watch]
Leading pharmaceutical firm AstraZeneca identifies Asia as growing market

Patents on blockbuster drugs have a shelf life, and competition from generic drugs is heating up. The pharmaceutical industry is facing some tough times as it struggles to come up with a steady pipeline of new medicines. But amid the gloom, UK pharmaceutical giant AstraZeneca, is staying positive....   more»


AstraZeneca »01/04/2009 [Company watch]
BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research

BioDuro and AstraZeneca announced today that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications....   more»


AstraZeneca »01/12/2009 [Company watch]
AstraZeneca to Move Production of Raw Materials for Drugs to China

AstraZeneca plans to move all production of the vital molecules in its medicines offshore, mainly to China. The pharmaceuticals company‚Äôs cost-cutting drive, which will continue for some years, means that it will cease to produce or source active pharmaceutical ingredients (API) in the UK....   more»


AstraZeneca »06/04/2010 [Company watch]
Werum Software installs PAS-X MES at AstraZeneca\'s Wuxi site

Lueneburg, Germany based Manufacturing Execution System (MES) software provider Werum Software & Systems has successfully finalized the installation of PAS-X MES in AstraZeneca\'s Wuxi site in the Jiangsu Province, China....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.